TY - STD TI - Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer lung Cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–11. https://doi.org/10.1016/j.jtho.2015.10.008. ID - ref1 ER - TY - JOUR AU - Meerbeeck, J. P. AU - Fennell, D. A. AU - Ruysscher, D. K. PY - 2011 DA - 2011// TI - Small-cell lung cancer JO - Lancet. VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)60165-7 DO - 10.1016/S0140-6736(11)60165-7 ID - Meerbeeck2011 ER - TY - JOUR AU - Glatzer, M. AU - Rittmeyer, A. AU - Muller, J. AU - Opitz, I. AU - Papachristofilou, A. AU - Psallidas, I. PY - 2017 DA - 2017// TI - Treatment of limited disease small cell lung cancer: the multidisciplinary team JO - Eur Respir J VL - 50 UR - https://doi.org/10.1183/13993003.00422-2017 DO - 10.1183/13993003.00422-2017 ID - Glatzer2017 ER - TY - STD TI - Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25. https://doi.org/10.1016/S1470-2045(17)30318-2. ID - ref4 ER - TY - STD TI - Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–24. https://doi.org/10.1056/NEJM199212033272302. ID - ref5 ER - TY - JOUR AU - Horn, L. AU - Mansfield, A. S. AU - Szczesna, A. AU - Havel, L. AU - Krzakowski, M. AU - Hochmair, M. J. PY - 2018 DA - 2018// TI - First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809064 DO - 10.1056/NEJMoa1809064 ID - Horn2018 ER - TY - JOUR AU - Li, Q. AU - Yuan, D. AU - Ma, C. AU - Liu, Y. AU - Ma, L. AU - Lv, T. PY - 2016 DA - 2016// TI - A new hope: the immunotherapy in small cell lung cancer JO - Neoplasma. VL - 63 UR - https://doi.org/10.4149/302_151001N511 DO - 10.4149/302_151001N511 ID - Li2016 ER - TY - STD TI - Sohn JH, Moon YW, Lee CG, Kim GE, Chung KY, Chang J, et al. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer. 2007;109(9):1845–950. https://doi.org/10.1002/cncr.22621. ID - ref8 ER - TY - JOUR AU - Turrisi, A. T. AU - Kim, K. AU - Blum, R. AU - Sause, W. T. AU - Livingston, R. B. AU - Komaki, R. PY - 1999 DA - 1999// TI - Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide JO - N Engl J Med VL - 340 UR - https://doi.org/10.1056/NEJM199901283400403 DO - 10.1056/NEJM199901283400403 ID - Turrisi1999 ER - TY - JOUR AU - Naidu, S. S. AU - Walker, P. R. AU - Parent, T. AU - Picton, M. E. PY - 2014 DA - 2014// TI - Limited-stage small cell lung cancer treated with cisplatin/irinotecan and concurrent thoracic radiation therapy JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/jco.2014.32.15_suppl.7598 DO - 10.1200/jco.2014.32.15_suppl.7598 ID - Naidu2014 ER - TY - STD TI - Fukuda M, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, et al. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(5):645–51. https://doi.org/10.1007/s00280-012-1952-5. ID - ref11 ER - TY - STD TI - Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106–13. https://doi.org/10.1016/S1470-2045(13)70511-4. ID - ref12 ER - TY - STD TI - Hong J, Park YM, Lee SH, Lee KC, Park SH, Park J, et al. Irinotecan and cisplatin combination chemotherapy plus concurrent thoracic irradiation for patients with limited disease small cell lung cancer. J Lung Cancer. 2011;10(1):49–55. https://doi.org/10.6058/jlc.2011.10.1.49. ID - ref13 ER - TY - STD TI - Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan thoracic oncology group 9902. J Clin Oncol. 2006;24(33):5247–52. https://doi.org/10.1200/JCO.2006.07.1605. ID - ref14 ER - TY - STD TI - Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol. 2005;23(15):3488–94. https://doi.org/10.1200/JCO.2005.01.082. ID - ref15 ER - TY - JOUR AU - Shin, A. AU - Oh, C. M. AU - Kim, B. W. AU - Woo, H. AU - Won, Y. J. AU - Lee, J. S. PY - 2017 DA - 2017// TI - Lung cancer epidemiology in Korea JO - Cancer Res Treat VL - 49 UR - https://doi.org/10.4143/crt.2016.178 DO - 10.4143/crt.2016.178 ID - Shin2017 ER - TY - STD TI - Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, et al. Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naive Korean patients with extensive-disease small cell lung cancer. Cancer Res Treat. 2019;51(1):119–27. https://doi.org/10.4143/crt.2018.019. ID - ref17 ER - TY - STD TI - Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5(6):867–73. https://doi.org/10.1097/jto.0b013e3181d95c87. ID - ref18 ER - TY - STD TI - Tamura K, Takada M, Kawase I, Tada T, Kudoh S, Okishio K, et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res. 1997;88(2):218–23. https://doi.org/10.1111/j.1349-7006.1997.tb00369.x. ID - ref19 ER - TY - STD TI - Jeong HC, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer. 2006;53(3):361–6. https://doi.org/10.1016/j.lungcan.2006.06.002. ID - ref20 ER - TY - JOUR AU - Yamada, M. AU - Kudoh, S. AU - Hirata, K. AU - Nakajima, T. AU - Yoshikawa, J. PY - 1998 DA - 1998// TI - Risk factors of pneumonitis following chemoradiotherapy for lung cancer JO - Eur J Cancer VL - 34 UR - https://doi.org/10.1016/S0959-8049(97)00377-8 DO - 10.1016/S0959-8049(97)00377-8 ID - Yamada1998 ER - TY - STD TI - Ohe Y, Yamamoto S, Suzuki K, Hojo F, Kakinuma R, Matsumoto T, et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer. 2001;37(1):54–63. https://doi.org/10.1016/S0959-8049(00)00350-6. ID - ref22 ER - TY - JOUR AU - Khozin, S. AU - Blumenthal, G. M. AU - Pazdur, R. PY - 2017 DA - 2017// TI - Real-world data for clinical evidence generation in oncology JO - J Natl Cancer Inst VL - 109 UR - https://doi.org/10.1093/jnci/djx187 DO - 10.1093/jnci/djx187 ID - Khozin2017 ER - TY - STD TI - Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(8):1147–57. https://doi.org/10.1016/S1470-2045(16)30104-8. ID - ref24 ER - TY - STD TI - Korkmaz T, Seber S, Kefeli U, Sari E, Canhoroz M, Oven B, et al. Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis. Clin Transl Oncol. 2013;15(7):535–40. https://doi.org/10.1007/s12094-012-0960-6. ID - ref25 ER - TY - STD TI - Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339. https://doi.org/10.1038/s41598-017-01571-0. ID - ref26 ER - TY - JOUR AU - Janssen-Heijnen, M. L. G. AU - Maas, H. A. A. M. AU - Schans, S. A. M. AU - Coebergh, J. W. W. AU - Groen, H. J. M. PY - 2011 DA - 2011// TI - Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it? JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq448 DO - 10.1093/annonc/mdq448 ID - Janssen-Heijnen2011 ER - TY - JOUR AU - Menendez, J. A. AU - Lupu, R. PY - 2007 DA - 2007// TI - Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2222 DO - 10.1038/nrc2222 ID - Menendez2007 ER - TY - STD TI - Rundle A, Madsen A, Orjuela M, Mooney L, Tang D, Kim M, et al. The association between benzo [a]pyrene-DNA adducts and body mass index, calorie intake and physical activity. Biomarkers. 2007;12(2):123–32. https://doi.org/10.1080/13547500601010418. ID - ref29 ER - TY - JOUR AU - Barbosa, A. D. AU - Savage, D. B. AU - Siniossoglou, S. PY - 2015 DA - 2015// TI - Lipid droplet-organelle interactions: emerging roles in lipid metabolism JO - Curr Opin Cell Biol VL - 35 UR - https://doi.org/10.1016/j.ceb.2015.04.017 DO - 10.1016/j.ceb.2015.04.017 ID - Barbosa2015 ER - TY - JOUR AU - Ruysscher, D. AU - Lueza, B. AU - Péchoux, C. AU - Johnson, D. H. AU - O'Brien, M. AU - Murray, N. PY - 2016 DA - 2016// TI - Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw263 DO - 10.1093/annonc/mdw263 ID - Ruysscher2016 ER -